EyePointEYPT -0.36%34 Gross Margin % is 24.14% as of Mar. 2026, which is 72% below its 10-year median of 86.81. GuruFocus rates EYPT with a GF Score™ of 34/100 and a GF Value™ of $0.83 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 737 Biotechnology companies, EyePoint ranks better than 67.71% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. EyePoint's Gross Profit for the
three
months ended in Mar. 2026 was $0.17 Mil. EyePoint's Revenue for the
three
months ended in Mar. 2026 was $0.70 Mil. Therefore, EyePoint's Gross Margin % for the quarter that ended in Mar. 2026 was 24.14%.
The historical rank and industry rank for EyePoint's Gross Margin % or its related term are showing as below:
EYPT'
s Gross Margin % Range Over the Past 10 Years
Min: 76.51 Med: 86.81 Max: 93.41
Current: 76.51
During the past 13 years, the highestGross Margin % of EyePoint was 93.41%. The lowest was 76.51%. And the median was 86.81%.
EYPT's Gross Margin % is ranked better than 67.71% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs EYPT: 76.51
EyePoint had a gross margin of 24.14% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for EyePoint was 3.40% per year.
EyePoint (NAS:EYPT) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
EyePoint had a gross margin of 24.14% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
EyePoint Gross Margin % Related Terms
EyePoint Gross Margin % Historical Data
* Premium members only.
The historical data trend for EyePoint's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EYPT vs AKTS, OLMA, ZBIO: Gross Margin % Comparison
For the Biotechnology subindustry, EyePoint's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EyePoint Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EyePoint's Gross Margin % distribution charts can be found below:
* The bar in red indicates where EyePoint's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
EyePoint (EYPT) has a Gross Margin % of 24.14% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on EyePoint and its competitors. This is 72% below median its historical median of 86.81. Over the past decade, EyePoint's Gross Margin % has ranged from 76.51 to 93.41. According to the industry distribution chart, EyePoint ranks #238 out of 737 companies in the Biotechnology industry, placing it in the top 32.3%.
Is EyePoint's Gross Margin % too high?
EyePoint's current Gross Margin % of 24.14% is 72% below median its 10-year median of 86.81. Over the past 10 years, this metric has ranged from a low of 76.51 to a high of 93.41. The Biotechnology industry median Gross Margin % is 60.92. EyePoint's value of 24.14% is 60.4% below this industry median. Based on the distribution chart, EyePoint ranks #238 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, EyePoint has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Gross Margin % compare to AKTS and OLMA?
According to the Biotechnology industry distribution chart, EyePoint ranks #238 out of 737 companies for Gross Margin %. This puts EyePoint in the upper half of its industry. The industry median Gross Margin % is 60.92. EyePoint's value of 24.14% is 60.4% below this benchmark. Historically, EyePoint's own Gross Margin % has ranged from 76.51 to 93.41 over the past decade. While the company's 10-year median is 86.81 vs. the industry median of 60.92, EyePoint has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EyePoint's current Gross Margin % of 24.14% is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on EyePoint and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EyePoint's current Gross Margin % is 24.14%, which is 72% below median its own 10-year median of 86.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (EYPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.83, compared to a current price of $13.66 — trading 1545.8% above its estimated fair value. The current Gross Margin % is 24.14%, which is 72% below median its 10-year median of 86.81 and 60.4% below the Biotechnology industry median of 60.92. EyePoint's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For EyePoint (EYPT), the current Gross Margin % is 24.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EyePoint (EYPT) Overvalued in 2026?
Based on GuruFocus' analysis, EyePoint stock appears to be overvalued.
The current stock price of $13.66 is trading 1545.8% above its estimated GF Value™ of $0.83.
GuruFocus considers EyePoint to be Significantly Overvalued.
Key valuation signals for EYPT:
Gross Margin %: 24.14% (72% below median its 10-year median of 86.81)
GF Value™: $0.83 vs. price of $13.66 (1545.8% above fair value)
Industry Position: 60.4% below the Biotechnology median (#238 of 737)
No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score
Get the complete analysis for EYPT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYPT has been successfully added to your 
